Angela Zink and Katinka Albrecht are at the German Rheumatism Research Centre (DRFZ), Epidemiology Unit, Charitéplatz 1, 10117 Berlin, Germany.
Checking for direct PDF access through Ovid
Early, targeted treatment improves the outcome of rheumatoid arthritis, reducing disease-associated disability and mortality. Until now, it was unknown whether these beneficial effects extended beyond 10 years following initial therapy. Could these effects persist even after 20 years?Refers to Gwinnutt, J. M. et al. The 20 year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: results from the Norfolk Arthritis register. Arthritis Rheumatol.http://dx.doi.org/10.1002/art.40090 (2017)